Serum Institute gains 20% in a non-needle tech startup WholeMedical

For an unknown sum, vaccine leader Serum Institute of India has purchased a 20% investment in medical device startup IntegriMedical to promote needle-free injection technology.According to a business statement, the technology helps patients who are afraid of needles by promoting patient compliance, decreasing needle-stick injuries, and improving the effectiveness of liquid medication through needle-free dispersion.After purchasing SCHOTT Kaisha's Indian partner in August 2021, Serum Institute of India (SII), which has been investing in backend businesses, was able to secure the company's supply of pharmaceutical packaging items, which include vials, syringes, ampoules, and cartridges required to package life-saving medication.According to the note, IntegriMedical has created the US-patented needle-free injection system (N-FIS), which uses a high-velocity jet stream and mechanical power to deliver medications and biologics reliably and efficiently. Without providing a timeframe, it was stated that N-FIS will be made available in the Indian private market, providing patients and healthcare professionals with an alternative to conventional needle-based injections.The Chief Executive of SII, Adar Poonawalla, stated that the organization was always looking for ways to invest in technologies that complemented its goals. "We envision a needle-free solution to deliver vaccines and believe that Integral's Needle-Free Injection Systems represent a significant advancement in drug delivery," he stated, going on to say that it would "potentially revolutionize the way we administer vaccines."The investment, according to IntegriMedical's managing director Sarvesh Mutha, is evidence of the promise of NFIS technology and its capacity to completely transform medicine delivery.

He continued by saying that SII's experience in vaccine production and international distribution would contribute to the technology's increased accessibility for patients everywhere. IntegriMedical's N-FIS is ISO 13485 certified and has obtained numerous regulatory approvals, including those from the CE (Europe) and CDSCO (India). The message further stated that the technology is patented in the United States. Additionally, it maintains manufacturing and research facilities in Hong Kong, India, and the United States. Ankur Naik, MD, of IntegriMedical, has played a key role in the N-FIS technology's development and clinical studies.